Daming ZhouWanwisa DejnirattisaiPiyada SupasaChang LiuAlexander J. MentzerHelen M. GinnYuguang ZhaoHelen M.E. DuyvesteynAekkachai TuekprakhonRungtiwa NutalaiBeibei WangGuido C. PaesenCesar Lopez-CamachoJose Slon-CamposBassam HallisNaomi CoombesKevin BewleySue CharltonThomas S. WalterDonal SkellySheila F. LumleyChristina DoldRobert LevinTao DongAndrew J. PollardJulian C. KnightDerrick CrookTeresa LambeElizabeth ClutterbuckSagida BibiAmy FlaxmanMustapha BittayeSandra Belij-RammerstorferSarah GilbertWilliam JamesMiles W. CarrollPaul KlenermanEleanor BarnesSusanna J. DunachieElizabeth E. FryJuthathip MongkolsapayaJingshan RenDavid I. StuartGavin R. ScreatonSiriraj HospitalMahidol Oxford Tropical Medicine Research UnitNIHR Oxford Biomedical Research CentreOxford University Hospitals NHS Foundation TrustPublic Health EnglandDiamond Light SourceWorthing HospitalUniversity of OxfordSir William Dunn School of PathologyNuffield Department of MedicineUniversity of Oxford Medical Sciences DivisionInstruct-ERIC2022-08-042022-08-042021-04-29Cell. Vol.184, No.9 (2021), 2348-2361.e610974172009286742-s2.0-85102634643https://repository.li.mahidol.ac.th/handle/20.500.14594/76204The race to produce vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began when the first sequence was published, and this forms the basis for vaccines currently deployed globally. Independent lineages of SARS-CoV-2 have recently been reported: UK, B.1.1.7; South Africa, B.1.351; and Brazil, P.1. These variants have multiple changes in the immunodominant spike protein that facilitates viral cell entry via the angiotensin-converting enzyme-2 (ACE2) receptor. Mutations in the receptor recognition site on the spike are of great concern for their potential for immune escape. Here, we describe a structure-function analysis of B.1.351 using a large cohort of convalescent and vaccinee serum samples. The receptor-binding domain mutations provide tighter ACE2 binding and widespread escape from monoclonal antibody neutralization largely driven by E484K, although K417N and N501Y act together against some important antibody classes. In a number of cases, it would appear that convalescent and some vaccine serum offers limited protection against this variant.Mahidol UniversityBiochemistry, Genetics and Molecular BiologyArticleSCOPUS10.1016/j.cell.2021.02.037